Ad
Monday, 6 November 2017
Bayer in bid to broaden use of anti-clotting drug Xarelto
FRANKFURT (Reuters) - German drugmaker Bayer on Monday moved to tap a potentially lucrative new market opportunity for its blockbuster clot prevention drug Xarelto, requesting approval in Europe to make atherosclerosis patients eligible for treatment.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment